Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

28.45 -1.33 (-4.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,738,744
Open 29.57
Bid (Size) 28.45 (100)
Ask (Size) 28.79 (200)
Prev. Close 29.78
Today's Range 28.04 - 29.81
52wk Range 22.96 - 43.15
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't ↗
This particular sector may suit cautious and aggressive investors. 
Via The Motley Fool
News headline image
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock ↗
The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals. 
Via The Motley Fool

Performance

YTD
-19.7%
-19.7%
1 Month
-11.9%
-11.9%
3 Month
-13.7%
-13.7%
6 Month
-26.2%
-26.2%
1 Year
+5.2%
+5.2%

More News

Read More
News headline image
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down ↗
Via The Motley Fool
Viking Therapeutics (NASDAQ:VKTX) Stock Holds Steady After Q1 2026 Earnings Miss on Higher Phase 3 Spending ↗
Via Chartmill
Topics Earnings
News headline image
The Smartest Growth Stocks to Buy With $2,000 Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 ↗
Via The Motley Fool
News headline image
Don't Buy Viking Therapeutics Stock Until You Read This ↗
Via The Motley Fool
News headline image
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗
Via The Motley Fool
News headline image
Is Viking Therapeutics a Top Takeover Target? ↗
Via The Motley Fool
News headline image
2 Stocks That Could Realistically Double by 2030 ↗
Via The Motley Fool
News headline image
Could Viking Therapeutics Be the Next Eli Lilly? ↗
Via The Motley Fool
News headline image
Best Weight Loss Drug Stocks to Buy in 2026 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party ↗
Via The Motley Fool
News headline image
Eli Lilly Stock: Next Stop $2,000? ↗
Via The Motley Fool
News headline image
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? ↗
Via The Motley Fool
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
Via Investor Brand Network
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
Via Investor Brand Network
News headline image
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
From BioMedWire
Via GlobeNewswire
News headline image
Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months ↗
Via The Motley Fool
News headline image
Eli Lilly Just Announced Fantastic News for Shareholders ↗
Via The Motley Fool
Topics Earnings
News headline image
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge ↗
Via MarketBeat
News headline image
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗
Via The Motley Fool
News headline image
This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street ↗
Via The Motley Fool
News headline image
Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗
Via The Motley Fool
News headline image
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
From Equity Insider
Via GlobeNewswire

Frequently Asked Questions

Is Viking Therapeutics, Inc. - Common Stock publicly traded?
Yes, Viking Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Viking Therapeutics, Inc. - Common Stock trade on?
Viking Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Viking Therapeutics, Inc. - Common Stock?
The ticker symbol for Viking Therapeutics, Inc. - Common Stock is VKTX on the Nasdaq Stock Market
What is the current price of Viking Therapeutics, Inc. - Common Stock?
The current price of Viking Therapeutics, Inc. - Common Stock is 28.45
When was Viking Therapeutics, Inc. - Common Stock last traded?
The last trade of Viking Therapeutics, Inc. - Common Stock was at 06/05/26 04:00 PM ET
What is the market capitalization of Viking Therapeutics, Inc. - Common Stock?
The market capitalization of Viking Therapeutics, Inc. - Common Stock is 2.83B
How many shares of Viking Therapeutics, Inc. - Common Stock are outstanding?
Viking Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.